Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 466 to 480 of 563 results for oral care

  1. QuikRead go for C-reactive protein testing in primary care (MIB78)

    NICE has developed a medtech innovation briefing (MIB) on the QuikRead go for C-reactive protein testing in primary care

  2. Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA768)

    Evidence-based recommendations on upadacitinib (Rinvoq) for treating active psoriatic arthritis in adults.

  3. Complicated intra-abdominal infections: ceftolozane/tazobactam (ESNM75)

    Summary of the evidence on ceftolozane/tazobactam for treating complicated intra-abdominal infections to inform local NHS planning and decision-making

  4. Virtual reality technologies for treating agoraphobia or agoraphobic avoidance: early value assessment (HTG701)

    Early value assessment (EVA) guidance on virtual reality technologies for treating agoraphobia or agoraphobic avoidance.

  5. Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management (NG240)

    This guideline covers recognising, diagnosing and managing bacterial meningitis and meningococcal disease in babies, children, young people and adults. It aims to reduce death and disability by helping healthcare professionals recognise meningitis and treat it quickly and effectively.

  6. Early and locally advanced breast cancer: diagnosis and management (NG101)

    This guideline covers diagnosing and managing early and locally advanced breast cancer. It aims to help healthcare professionals offer the right treatments to people, taking into account the person's individual preferences.

  7. Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy (TA886)

    Evidence-based recommendations on olaparib (Lynparza) for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy in adults.

  8. Tofacitinib for moderately to severely active ulcerative colitis (TA547)

    Evidence-based recommendations on tofacitinib (Xeljanz) for previously treated moderately to severely active ulcerative colitis in adults.

  9. Amantadine, oseltamivir and zanamivir for the treatment of influenza (TA168)

    Evidence-based recommendations on amantadine (Lysovir), oseltamivir (Tamiflu) and zanamivir (Relenza) for treating influenza in children and adults.

  10. Aptiva for painful diabetic neuropathy (MIB119)

    NICE has developed a medtech innovation briefing (MIB) on Aptiva for painful diabetic neuropathy .

  11. Guide to the methods of technology appraisal 2013 (PMG9)

    This guide provides an overview of the principles and methods of health technology assessment and appraisal within the context of the NICE appraisal process

  12. Heart valve disease presenting in adults: investigation and management (NG208)

    This guideline covers investigation and management of heart valve disease presenting in adults. It aims to improve quality of life and survival for people with heart valve disease through timely diagnosis and appropriate intervention.

  13. MolecuLight i:X for wound imaging (MIB212)

    NICE has developed a medtech innovation briefing (MIB) on MolecuLight i:X for wound imaging .

  14. HealthVCF for detecting vertebral compression fractures on CT scans (MIB267)

    NICE has developed a medtech innovation briefing (MIB) on HealthVCF for detecting vertebral compression fractures on CT scans .

  15. Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy (TA850)

    Evidence-based recommendations on amivantamab (Rybrevant) for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy in adults.